Analysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Target Price at $137.15

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been given a consensus recommendation of “Moderate Buy” by the fifteen research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $137.1538.

Several research firms recently issued reports on ABVX. Wedbush began coverage on Abivax in a research note on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price objective for the company. Jefferies Financial Group began coverage on Abivax in a research note on Monday, March 16th. They set a “buy” rating and a $160.00 price objective for the company. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday. Oddo Bhf reissued an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Finally, Barclays raised their price target on Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th.

Institutional Investors Weigh In On Abivax

A number of large investors have recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. raised its position in Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after purchasing an additional 140 shares in the last quarter. WPG Advisers LLC raised its position in Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares in the last quarter. Assetmark Inc. raised its position in Abivax by 41.5% during the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock valued at $99,000 after purchasing an additional 260 shares in the last quarter. SmartHarvest Portfolios LLC raised its position in Abivax by 11.6% during the first quarter. SmartHarvest Portfolios LLC now owns 2,696 shares of the company’s stock valued at $300,000 after purchasing an additional 280 shares in the last quarter. Finally, Personal CFO Solutions LLC raised its position in Abivax by 10.5% during the first quarter. Personal CFO Solutions LLC now owns 3,027 shares of the company’s stock valued at $337,000 after purchasing an additional 288 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Stock Performance

NASDAQ:ABVX opened at $121.99 on Tuesday. The firm has a market capitalization of $9.72 billion, a price-to-earnings ratio of -23.41 and a beta of 0.84. Abivax has a 52-week low of $5.59 and a 52-week high of $148.83. The stock has a fifty day moving average of $117.74 and a 200 day moving average of $118.98.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, May 25th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. Equities analysts forecast that Abivax will post -3.84 earnings per share for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.